Gilead's Oncology Ambitions Advance as Trodelvy-Keytruda Combo Shows Promise in Aggressive Breast Cancer
Gilead Sciences reports compelling Phase 3 data for its Trodelvy immunotherapy combined with Merck's Keytruda in frontline metastatic triple-negative breast cancer, marking a significant stride in its strategic pivot to expand beyond virology. The company also bolsters its pipeline through a new partnership with Repare Therapeutics.